Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing genetic medicines for neuromuscular and inherited retinal diseases. The company utilizes its proprietary Endosomal Escape Vehicle (EEV) platform to deliver oligonucleotide therapeutics to intracellular targets. Its clinical pipeline focuses on Duchenne muscular dystrophy (DMD) with programs ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51, as well as myotonic dystrophy type 1 (DM1) through the VX-670 program in partnership with Vertex Pharmaceuticals. In the ocular space, the company is advancing ENTR-801 for Usher syndrome type 2A. Entrada operates in the United States, United Kingdom, and European Union, targeting patients with rare genetic conditions.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage entradatx.com
Sector Healthcare IR page ir.entradatx.com
Tags
neuromuscular diseases, inherited retinal diseases, oligonucleotide therapeutics, intracellular delivery, rare diseases, genetic medicines, duchenne muscular dystrophy, myotonic dystrophy, usher syndrome, ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51, VX-670, ENTR-801, EEV Platform, Vertex Pharmaceuticals
Press page —

Metrics

Valuation  
Market cap $ 248.605M
Market cap (USD) $ 248.605M
P/E -1.65
PEG —
P/BV 1.25
P/S 62.51
P/OCF -1.82
P/FCF -1.83
Dividend yield —
Turnover / mcap —
Returns  
ROE -39.1%
ROI -54.8%
ROIC -45.1%
Profit margin -565.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -73.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 25.421M 210.782M 129.013M — — —
Net profit -143.75M 65.626M -6.685M -94.616M -51.158M -26.523M
Free cash flow -129.553M -44.715M 134.189M -96.673M -55.442M -27.888M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 10.28 17.29 15.09 13.52 17.12 —
Price performance 12m -0.41 0.15 0.12 -0.21 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 0.00 25.9M 68.2M 59.2M 50.9M
Cash and deposits (USD) 16.8M 39M 291M 45.2M 67.6M 101M 90.4M
Right-of-use assets (USD) — — 0.00 25.3M 81.5M 71.1M 60.5M
Cash flow detail
Operating cash flow (USD) — -25.6M -50.9M -93.8M 140M -41.6M -129M
Purchases of property, plant and equipment (USD) — -2.32M -4.58M -2.89M -5.61M -3.16M -1.04M
Income taxes paid (cash effect) (USD) — — — 0.00 -14.7M -4.62M -1.7M
Share-based compensation (USD) — 325,000 2.53M 9.9M 13.1M 17.9M 19.6M
Free cash flow (OCF - PPE - intangibles) (USD) — -27.9M -55.4M -96.7M 134M -44.7M -130M
Income detail
Research and development expense (USD) — 21.1M 35.9M 66.6M 99.9M 125M 142M
↳ 5y CAGR +46.5%
Total comprehensive income (USD) — — -51.2M -96.7M -4.43M 65.4M -143M
Comprehensive income to owners (USD) — — -51.2M -96.7M -4.43M 65.4M -143M
Reported Dec 9, 2021 Mar 15, 2022 Mar 6, 2023 Mar 13, 2024 Mar 13, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Share Facebook Twitter LinkedIn Email this page

-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 --

-- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027 –

-- ELEVATE-45-201 Cohort 1 data reported in October 2026 met the primary objective of favorable safety and tolerability at an initial dose of 5 mg/kg --

-- ELEVATE-45-201 Cohort 2 enrollment complete and Company on track to report data in H1 2027 --

-- Expected cash runway extended into Q4 2027 with $193 million in cash, cash equivalents and marketable securities as of September 30, 2026 --

BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the third quarter ended September 30, 2026, and highlighted recent business updates.

“The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics. “With these initial dose cohorts supporting the safety profile of our lead Duchenne programs, our attention now turns to the next set of readouts designed to further define the potential of our investigational medicines. We expect the ELEVATE-44-201 Cohort 1 open-label data to provide important insights into the underlying biology and the durability of the early functional improvements observed to date. The ELEVATE-44-201 Cohort 1 open-label data readout will also include additional functional measures, reflecting nearly a year of treatment. Cohort 2 data from ELEVATE-44-201 and ELEVATE-45-201 will then further characterize the relationship between dose, exon skipping, dystrophin production and functional outcomes at both higher doses and exposure levels.”

Mr. Doshi continued, “Including the anticipated Phase 1/2 clinical data from our partner Vertex’s GALILEO study in myotonic dystrophy type 1 during the second half of 2026, we expect four clinical data readouts through the first half of 2027. This marks an important period of clinical catalysts for Entrada as we advance our pipeline and work toward our goal of delivering potentially transformative medicines to people living with serious neuromuscular diseases.”

Recent Corporate Highlights

Clinical-Stage Development Pipeline: Entrada continues to advance multiple clinical programs in people living with Duchenne muscular dystrophy (DMD) in the U.K., EU and U.S., complementing the ongoing clinical progress of its myotonic dystrophy type 1 (DM1) partnership (VX-670) with Vertex.

ELEVATE-44-201

  • Cohort 1 (6 mg/kg): The Company expects to receive data from the Cohort 1 open-label period of the study by year-end 2026. The open-label period of the study will assess longer-term safety and other functional measures commonly evaluated in DMD clinical studies and will include all participants in the multiple ascending dose (MAD) period who subsequently rolled over to ENTR-601-44. All Cohort 1 participants have received their final dose in the open-label period and rolled into the long-term extension (LTE) study. Previously announced data from the MAD portion of Cohort 1 achieved the primary objective of favorable safety and tolerability, with no discontinuations and no serious adverse events.

  • Cohort 2 (12 mg/kg): Enrollment is complete and dosing is ongoing for Cohort 2, with data expected in the first quarter of 2027.

  • Cohort 3 (18 mg/kg): In October 2026, the Company announced that an independent Data Monitoring Committee (DMC) reviewed available safety data and recommended initiating Cohort 3 at the highest planned dose, and enrollment is ongoing.

ELEVATE-44-102: The Company believes this clinical study, in the underserved adult patient population, would best be initiated at the highest advisable starting dose in patients with advanced disease. Following a review of safety, pharmacokinetic and pharmacodynamic data from its lead programs in the U.K. and EU, the Company will continue to engage with the FDA and provide an update on the clinical study design and timing when appropriate.

ELEVATE-45-201

  • Cohort 1 (5 mg/kg): In October 2026, the Company reported positive data from Cohort 1 of the global Phase 1/2 MAD clinical study of ENTR-601-45 in ambulatory participants living with DMD who are amenable to exon 45 skipping. Study participants in Cohort 1 received three doses of 5 mg/kg of ENTR-601-45 or placebo. Topline results met the primary objectives of favorable safety and tolerability. Headache was the most common treatment-emergent adverse event (TEAE); one participant experienced two serious TEAEs (vomiting and pyrexia) which subsequently resolved, and there were no study discontinuations. No hypomagnesemia or renal safety concerns were noted and plasma ENTR-601-45 exposures were consistent with those predicted by juvenile non-human primate data. The secondary objectives also met Company expectations. All study participants in Cohort 1 have now progressed to the open-label, Phase 2 portion of the study, where they will receive six doses of 5 mg/kg of ENTR-601-45.

  • Cohort 2 (10 mg/kg): Enrollment is complete and dosing is ongoing for Cohort 2, with data expected in the first half of 2027.

  • Cohort 3 (up to 15 mg/kg): Data from Cohort 3 to follow pending an independent DMC’s review of all available safety data from Cohort 2 (10 mg/kg), with the potential to recommend initiating Cohort 3 at up to 15 mg/kg.

  • In October 2026, the U.S. FDA Office of Orphan Products Development (OOPD) granted orphan drug designation for ENTR-601-45 for the treatment of DMD.

ELEVATE-LTE

  • ELEVATE-44-201 and ELEVATE-45-201 study participants are eligible to participate in a LTE platform study (ENTR-DMD-202) following completion of the open-label dosing period.

  • The LTE study protocol, accepted by U.K. and European authorities, enables study participants continued access to ENTR-601-44 and ENTR-601-45 and provides for the collection of longer-term safety and efficacy data, including functional measures.

ELEVATE-50-201 and ENTR-601-51: The Company expects to submit additional regulatory applications following a review of data from the ongoing studies of its lead programs. The Company is evaluating a variety of options to optimize clinical study execution and expects to provide more specific timeline guidance as the new strategy is finalized.

VX-670: Vertex has completed enrollment and dosing in the MAD portion of the GALILEO global Phase 1/2 clinical trial of VX-670 in people with DM1. The study is assessing both safety and preliminary efficacy, as measured by the change from baseline in the splicing index on muscle biopsy as well as other endpoints, including those that evaluate muscle function and strength, such as video hand opening time (vHOT) and quantitative muscle testing (QMT) score. Vertex is on track to share interim results from the GALILEO study in the second half of 2026.

Expanding Preclinical Pipeline: The Company has generated compelling preclinical data from programs focused on ocular and metabolic diseases. The pipeline includes the advancement of two novel oligonucleotide-based programs for the potential treatment of inherited retinal diseases, where there exists high unmet need. The Company announced its first ocular candidate, ENTR-801, for the potential treatment of Usher syndrome type 2A (USH2A) and plans to nominate a second clinical candidate for an ocular disease by year-end 2026.

Upcoming Investor Conferences

  • Guggenheim Healthcare Innovation Conference, Boston, MA on November 9, 2026

  • Evercore Healthcare Conference, Miami, FL on December 1, 2026

Third Quarter 2026 Financial Results

Cash Position: Cash, cash equivalents and marketable securities were $193.0 million as of September 30, 2026, compared to $295.7 million as of December 31, 2025. The decrease was primarily driven by cash used to fund operations. Based on current operating plans, the Company believes that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its operations into the fourth quarter of 2027.

Collaboration Revenue: Collaboration revenue was $0.9 million for the third quarter of 2026, compared to $1.6 million for the same period in 2025.

Research & Development (R&D) Expenses: R&D expenses were $32.4 million for the third quarter of 2026, compared to $38.4 million for the same period in 2025. The decrease was primarily driven by lower preclinical costs for the Company’s Duchenne programs and lower facility-related costs.

General & Administrative (G&A) Expenses: G&A expenses were $10.2 million for the third quarter of 2026, compared to $10.3 million for the same period in 2025. The decrease was primarily driven by lower professional services costs.

Net Loss: Net loss was $39.7 million for the third quarter of 2026, compared to $44.1 million for the same period in 2025.

Patients and Their Care Partners Patients and their care partners are a critical part of our community, and we are committed to keeping them informed and connected. To receive community updates in real time and read today’s quarterly update, please visit Community Updateson our corporate website.

About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share Facebook Twitter LinkedIn Email this page

Linea Aspesi

Linea Aspesi

Linea Aspesi

A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer.

“Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “We are in a catalyst-rich period with our neuromuscular programs, and Linea brings deep experience that will be invaluable as we continue to build an industry-leading culture that enables Entradans to do their best work and deliver on the potential of our pipeline. People are the foundation of any organization, and at Entrada, we know that a strong and engaged team is critical to our ability to develop a new class of genetic medicines and ultimately bring them to the patients who need them most.”

“Entrada is a company with a clear and steady commitment to patients and to one another,” said Ms. Aspesi. “I’m thrilled to join the team at such an important time in Entrada’s growth and look forward to building on its strong, mission-driven culture and fostering an environment where our colleagues can continue to do their best work as we grow and advance our pipeline for patients.”

Ms. Aspesi is an organizational leader with more than twenty years of experience driving culture transformation at biopharmaceutical and technology companies ranging from small-cap to Fortune 500. With a focus on scaling organizations from discovery through commercial stages, she has led companies through critical inflection points while executing culture strategies that put people first and drive employee engagement and retention. Prior to Entrada, Ms. Aspesi served as Chief People Officer at KalVista Pharmaceuticals (acquired by Chiesi Group) and held multiple executive-level human resources leadership roles at life science companies including Editas Medicine, Forma Therapeutics, Inc. (acquired by Novo Nordisk), Saniona, Inc., Sobi, Inc., and Genzyme Biologics Manufacturing (acquired by Sanofi). Ms. Aspesi holds a BA in Education from the University of Massachusetts, Amherst.

About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share Facebook Twitter LinkedIn Email this page

-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --

-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 --

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiating Cohort 3 at the top dose of 18 mg/kg, an increase from 12 mg/kg in Cohort 2 and 6 mg/kg in Cohort 1. ELEVATE-44-201 is a Phase 1/2 MAD clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in participants with a confirmed mutation in the DMD gene amenable to exon 44 skipping.

“The independent Data Monitoring Committee’s recommendation to advance to Cohort 3 at the top dose of 18 mg/kg marks another important step in the clinical development of ENTR-601-44,” said Natarajan Sethuraman, PhD, President of Research and Development at Entrada Therapeutics. “This recommendation allows us to continue dose escalation in the ELEVATE-44-201 clinical study and deepen our understanding of ENTR-601-44’s safety, pharmacokinetic and pharmacodynamic profile, as dosing at 18 mg/kg could lead to meaningfully higher exposure, dystrophin production and functional benefit. We look forward to receiving data later this year from Cohort 1 participants after one year of treatment in the open-label period, followed by Cohort 2 data in the first quarter of 2027.”

About the ELEVATE-44-201 Phase 1/2 Study ELEVATE-44-201 is a global, two-part, randomized, double-blind, placebo-controlled Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-44 in ambulatory participants aged four to 20 with Duchenne who are amenable to exon 44 skipping. The multiple ascending dose (MAD) Part A portion of the study is evaluating the safety, pharmacokinetics, pharmacodynamics and functional parameters following intravenous administration of ENTR-601-44 to study participants in three cohorts at sites in the U.K. and EU.

About ENTR-601-44 ENTR-601-44 is a proprietary Endosomal Escape Vehicle (EEV™)-conjugated oligonucleotide that has a sequence designed and optimized for people with a confirmed mutation in the DMD gene that is amenable to exon 44 skipping, which comprises approximately eight percent of the Duchenne patient population globally. ENTR-601-44 is designed to address the underlying cause of Duchenne, facilitating production of functional dystrophin from the endogenous (naturally occurring) DMD gene.

In December 2025, the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to ENTR-601-44.

Patients and Their Care Partners Patients and their care partners are a critical part of our community, and we are committed to keeping them informed and connected. To receive community updates in real time and read today’s update, please visit Community Updates on our corporate website.

About Duchenne Muscular Dystrophy (DMD) Duchenne muscular dystrophy (DMD) is a rare disease caused by mutations in the DMD gene, which encodes the dystrophin protein. These mutations lead to inadequate dystrophin production. Dystrophin is essential to maintaining the structural integrity and function of muscle cells. Lack of functional dystrophin leads to progressive loss of muscle strength, impacting mobility and causing heart or respiratory complications that contribute to high mortality rates. An estimated 41,000 people in the U.S. and Europe are living with DMD. Of those, approximately 11,500 are amenable to skipping of exon 44, 45, 50, or 51.

About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Prompts

Entrada Therapeutics, Inc. (ticker TRDA), listed in United States.

Company History

Date Change Detail
Dec 26, 2018 Renamed CycloPorters, Inc. → ENTRADA THERAPEUTICS, INC.

ETFs Holding Entrada Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 67,621 $ 338.105K Nov 16, 2026
DXUV 0.00% 18,985 $ 98.152K Nov 12, 2026
DFAS 0.00% 89,898 $ 464.773K Nov 12, 2026
DFSU 0.00% 3,020 $ 15.613K Nov 12, 2026
DFAU 0.00% 4,896 $ 25.312K Nov 12, 2026
DFSV 0.00% 9,553 $ 49.389K Nov 12, 2026
DCOR 0.00% 4,231 $ 21.874K Nov 12, 2026
AVUS 0.00% 6,979 $ 34.895K Nov 16, 2026
AVSU 0.00% 742 $ 3,710.00 Nov 16, 2026